SCHEMBL2856594

SCHEMBL2856594

O=C1OC(c2ccccc2)(c2ccccc2)C2CNCCN12

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.47
ADRB2 P07550 1/20 0.43
APLNR P35414 1/20 0.43
GLP1R P43220 1/20 0.43
FFAR4 Q5NUL3 1/20 0.43
GPR119 Q8TDV5 1/20 0.43
HTR2C P28335 13/20 0.40
HTR2B P41595 11/20 0.40
HTR2A P28223 8/20 0.40
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38
CHRM2 P08172 1/20 0.36
CHRM3 P20309 1/20 0.36
HSD11B1 P28845 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2867919 0.92 NPSR1 (0.46) NPSR1ADRB2APLNRGLP1RFFAR4
SCHEMBL2858341 0.86 NPSR1 (0.44) NPSR1ADRB2APLNRGLP1RFFAR4
SCHEMBL2859274 0.86 HTR2C (0.40) NPSR1ADRB2APLNRGLP1RFFAR4
SCHEMBL2868956 0.84 KCNN4 (0.40) NPSR1ADRB2APLNRGLP1RFFAR4
SCHEMBL23052957 0.78 NPSR1 (0.50) NPSR1ADRB2APLNRGLP1RFFAR4
SCHEMBL2858342 0.77 SLC6A2 (0.44) NPSR1HTR2CHTR2BHTR2ASLC6A2
Hydrochloric Acid SCHEMBL2868925 0.76 NPSR1 (0.60) NPSR1ADRB2APLNRGLP1RFFAR4
SCHEMBL2865912 0.72 HTR2C (0.37) HTR2CHTR2BHTR2A
SCHEMBL30803937 0.72 HTR2C (0.35) HTR2CHTR2BHTR2A
Hydrochloric Acid SCHEMBL2865785 0.71 NPSR1 (0.58) NPSR1ADRB2APLNRGLP1RFFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4711395-A2 POLYMERIZABLE COMPOSITION FOR OPTICAL MATERIAL, POLYMERIZABLE PREPOLYMER COMPOSITION FOR OPTICAL MATERIAL, CURED PRODUCT, AND METHOD FOR PRODUCING OPTICAL MATERIAL Mitsui Chemicals, Inc. (JP) 2026-03-18 EP disclosed
EP-4101876-B1 POLYMERIZABLE COMPOSITION FOR OPTICAL MATERIAL, POLYMERIZABLE PREPOLYMER COMPOSITION FOR OPTICAL MATERIAL, CURED OBJECT, AND METHOD FOR PRODUCING OPTICAL MATERIAL MITSUI CHEMICALS INC (JP) 2026-03-04 EP disclosed
US-20230111506-A1 POLYMERIZABLE COMPOSITION FOR OPTICAL MATERIAL, POLYMERIZABLE PREPOLYMER COMPOSITION FOR OPTICAL MATERIAL, CURED PRODUCT, AND METHOD FOR PRODUCING OPTICAL MATERIAL MITSUI CHEMICALS, INC. (JP) 2023-04-13 US disclosed
EP-4101876-A1 POLYMERIZABLE COMPOSITION FOR OPTICAL MATERIAL, POLYMERIZABLE PREPOLYMER COMPOSITION FOR OPTICAL MATERIAL, CURED OBJECT, AND METHOD FOR PRODUCING OPTICAL MATERIAL Mitsui Chemicals, Inc. (JP) 2022-12-14 EP disclosed
EP-2261033-B1 Method of preparing lithographic printing plate FUJIFILM CORP (JP) 2014-08-27 EP disclosed
EP-2261033-A1 Method of preparing lithographic printing plate Fujifilm Corporation (JP) 2010-12-15 EP disclosed
US-7795267-B2 Bicyclic piperazine compound having TGR23 antagonistic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-14 US disclosed
US-7750162-B2 Process for preparation of nonnatural amino acid and intermediate thereof DAISO CO., LTD. (JP) 2010-07-06 US disclosed
US-20070208180-A1 Process for Preparation of Nonnatural Amino Acid and Intermediate Thereof DAISO CO., LTD. (JP) 2007-09-06 US disclosed
US-20070072865-A1 Bicyclic piperazine compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-29 US disclosed
US-20070072096-A1 Negative curable dye-containing composition, color filter, and method of manufacturing the same FUJI PHOTO FILM CO., LTD. 2007-03-29 US disclosed
EP-1739077-A1 PROCESS FOR PRODUCTION OF NONNATURAL AMINO ACIDS AND INTERMEDIATES THEREFOR DAISO CO., LTD. (JP) 2007-01-03 EP disclosed
EP-1661898-A1 BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208180-A1 Process for Preparation of Nonnatural Amino Acid and Intermediate Thereof BCAT1, BCAT2, AADAT NPSR1 480/4885ADRB2 1859/4885APLNR 593/4885
US-20070072865-A1 Bicyclic piperazine compound and use thereof GPR3, FFAR3, LPAR3 NPSR1 211/4885ADRB2 449/4885APLNR 136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.